Fetal calf serum and epidermal growth factor prevent the inhibitory action of a chalone-like growth inhibitor for Ehrlich ascites mammary carcinoma cells in vitro
- PMID: 6240265
Fetal calf serum and epidermal growth factor prevent the inhibitory action of a chalone-like growth inhibitor for Ehrlich ascites mammary carcinoma cells in vitro
Abstract
A growth inhibitor for the Ehrlich ascites mammary carcinoma, purified from bovine mammary gland, is antagonized by very low concentrations of epidermal growth factor (2-16 X 10(-10) M) or fetal calf serum (0.001-0.1%). Thus, epidermal growth factor and the compounds in fetal calf serum have the same effect as earlier described for insulin and proinsulin [1-3].
Similar articles
-
Is ribonucleotide reductase in Ehrlich ascites mammary tumour cells the target of a growth inhibitor purified from bovine mammary gland?Biomed Biochim Acta. 1984;43(12):1377-83. Biomed Biochim Acta. 1984. PMID: 6398699
-
On a "chalone"-like factor for Ehrlich ascites mammary carcinoma.Acta Biol Med Ger. 1980;39(1):93-105. Acta Biol Med Ger. 1980. PMID: 6448529
-
Response of different mammary epithelial cell lines to a mammary derived growth inhibitor (MDGI).Biomed Biochim Acta. 1989;48(1):143-51. Biomed Biochim Acta. 1989. PMID: 2775246
-
Transforming growth factor alpha and mouse models of human breast cancer.Oncogene. 2000 Feb 21;19(8):1085-91. doi: 10.1038/sj.onc.1203278. Oncogene. 2000. PMID: 10713694 Review.
-
The role of epidermal growth factor in normal and neoplastic growth of mouse mammary epithelial cells.Cancer Treat Res. 1988;40:343-62. doi: 10.1007/978-1-4613-1733-3_16. Cancer Treat Res. 1988. PMID: 2908659 Review. No abstract available.